HOME >> MEDICINE >> NEWS
Takeda responds to the FDA advisory committee recommendation

Deerfield, IL, July 30, 2007 Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS ; (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

The breadth and depth of ACTOS data encompassing more than 16,000 patients over the past 10 yearsis consistent: Short- and long-term studies, both prospective and observational, studies in both humans and animals, all have shown no evidence that ACTOS is associated with an increased risk of heart attack or stroke, said Mehmood Khan, M.D., TGRD president. Critical in this body of data is the PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) study, since the only scientific way to determine a medications safety is a prospective, long-term trial.

About the PROactive Study

PROactive was a prospective, randomized, placebo-controlled outcomes trial. The PROactive study included 5,238 patients with type 2 diabetes and a history of macrovascular disease, who were force titrated up to 45 mg daily of either ACTOS or placebo. In this study, there was no difference in the number of macrovascular events between standard of care and ACTOS, and standard of care alone. Although there was no statistically significant difference between ACTOS and standard of care for the primary endpoint, there was no increase in mortality or total macrovascular events with ACTOS.

The ACTOS Prescribing Information was recently revised by the FDA to include this reassuring cardiovascular safety data. ACTOS is the only thiazolidinedione (TZD) with safety data from a cardiovascular outcomes trial in its label.

Although drugs may be in the same class, they also can have different clinical effects due to differences
'"/>

Contact: Cristina Sotolongo
Cristina.Sotolongo@ketchum.com
646-935-4021
Ketchum
30-Jul-2007


Page: 1 2

Related medicine news :

1. Takeda submits new drug application for extended-release type 2 diabetes medication, ACTOplus met
2. Takeda submits new drug application for combination type 2 diabetes medication
3. Stubborn ulcerative colitis responds to arthritis drug, review finds
4. American Egg Board responds to proposed USDA rule to revise WIC food package
5. Bradley Hospital responds to FDA report on ADHD drugs
6. Life-threatening lupus responds to stem cell transplant therapy
7. Pain research using electronic diaries helps identify who responds to placebo effect
8. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
9. ARRS president responds to NAS report on ionizing radiation
10. Medical, IT, engineering experts form advisory panel for electronic health record safety
11. National Academies advisory: Native African vegetables

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2018)... ... August 31, 2018 , ... “Vitamin D is the Key: The ... debuted as a hot new release in Vitamins and Supplements, Medical Atlases, Vitamins, Medical ... on a media tour around the United States. , With all the medical advancements ...
(Date:9/1/2018)... ... August 31, 2018 , ... Alice Branton shared her ... research health issues with Daytime host Jerry Penacoli. , With all the medical ... Vitamin D deficiency is a major public health problem worldwide irrespective of age, location, ...
(Date:8/31/2018)... CHICAGO (PRWEB) , ... August 31, 2018 , ... ... community hospitals | 2018" list. , This list includes independent community hospitals as ... geographies, while others care for small communities outside of large cities. The hospitals ...
(Date:8/31/2018)... ... August 31, 2018 , ... Kessler Foundation, ... addition of an MRI Simulator. In the MRI Simulator, the individual experiences the ... in this mock scan experience, research participants become accustomed to the sights and ...
(Date:8/31/2018)... VALLEY, Pa. (PRWEB) , ... August 31, 2018 ... ... to those offered by the American Heart Association (AHA) to be responsive for ... business concerns and purchasing managers may now reap the benefits. Companies like Pacific ...
Breaking Medicine News(10 mins):
(Date:8/31/2018)... ... ... Power Systems, a leading provider of fitness and performance products, and Spartan, ... mission to motivate 100 million people to get off their couches and get moving. ... competitors a fun and complete physical challenge. Spartan saw the need and the opportunity ...
(Date:8/31/2018)... ... August 31, 2018 , ... The Centers for Disease ... years of expertise in delivering comprehensive wellness engagement solutions, has been selected as ... Health will receive a $40,000 grand prize for its winning proposal, Closing the ...
(Date:8/31/2018)... ... August 31, 2018 , ... Yisrayl Hawkins, Pastor and Overseer at ... details Feast of Tabernacles topics and events. He says polls show the world is ... Feast of Tabernacles. , Yisrayl says The House of Yahweh has been asked ...
Breaking Medicine Technology:
Cached News: